The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients

Health Policy

Volumn 96, Issue 2, 2010, Pages 170-177

  Hiligsmann, Mickaël ^a   Rabenda, Véronique ^a   Bruyère, Olivier ^a   Reginster, Jean Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Adherence; Compliance; Cost effectiveness; Economic analysis; Health policy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT REFUSAL; AGED; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; FRACTURE; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL; STATISTICS; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COSTS; FEMALE; FRACTURES, BONE; HUMANS; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 79952032073     PISSN: 01688510     EISSN: 18726054     Source Type: Journal    
DOI: 10.1016/j.healthpol.2010.01.014     Document Type: Article

References (60)

1. Cleemput I., Kesteloot K., DeGeest S. A review of the literature on the economics of noncompliance. Room for methodological improvement. Health Policy 2002, 59:65-94.
2. Hughes D.A., Bagust A., Haycox A., Walley T. Accounting for noncompliance in pharmacoeconomic evaluations. Pharmacoeconomics 2001, 19:1185-1197.
3. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
4. Hughes D.A., Bagust A., Haycox A., Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Economics 2001, 10:601-615.
5. Vrijens B., Vincze G., Kristanto P., Urquhart J., Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008, 336:1114-1117.
6. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359:2018-2026.
7. McClung M.R., Geusens P., Miller P.D., Zippel H., Bensen W.G., Roux C., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. New England Journal of Medicine 2001, 344:333-340.
8. Reginster J., Minne H.W., Sorensen O.H., Hooper M., Roux C., Brandi M.L., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporosis International 2000, 11:83-91.
9. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
10. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998, 280:2077-2082.
11. National Institute for Health and Clinical Excellence (NICE), Systematic reviews of clinical effectiveness prepared for the guideline 'Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk': National Institute for Health and Clinical Excellence; 2008. Available from: [Accessed July 15, 2009]. http://nice.org.uk/nicemedia/pdf/OsteoporosisEvidenceReviews190908.pdf.
12. Cranney A., Guyatt G., Griffith L., Wells G., Tugwell P., Rosen C. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 2002, 23:570-578.
13. Siris E.S., Selby P.L., Saag K.G., Borgstrom F., Herings R.M., Silverman S.L. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. American Journal of Medicine 2009, 122:S3-S13.
14. Rabenda V., Hiligsmann M., Reginster J.Y. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opinion on Pharmacotherapy 2009, 10:2303-2315.
15. Weycker D., Macarios D., Edelsberg J., Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporosis International 2006, 17:1645-1652.
16. Lekkerkerker F., Kanis J.A., Alsayed N., Bouvenot G., Burlet N., Cahall D., et al. Adherence to treatment of osteoporosis: a need for study. Osteoporosis International 2007, 18:1311-1317.
17. Siris E.S., Harris S.T., Rosen C.J., Barr C.E., Arvesen J.N., Abbott T.A., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings 2006, 81:1013-1022.
18. Rabenda V., Mertens R., Fabri V., Vanoverloop J., Sumkay F., Vannecke C., et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporosis International 2008, 19:811-818.
19. Hiligsmann M., Ethgen, Bruyère O., Richy F., Gathon H.J., Reginster J.Y. Development and validation of a Markov microsimulation model for the economic evaluation of treatments in osteoporosis. Value Health 2009, 12:687-696.
20. Cleemput I., van Wilder P., Huybrechts M., Vrijens F. Belgian methodological guidelines for pharmacoeconomic evaluations: toward standardization of drug reimbursement requests. Value Health 2009, 441-449.
21. Hiligsmann M., Bruyere O., Ethgen O., Gathon H.J., Reginster J.Y. Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women. Bone 2008, 43:991-994.
22. Autier P., Haentjens P., Bentin J., Baillon J.M., Grivegnee A.R., Closon M.C., et al. Costs induced by hip fractures: a prospective controlled study in Belgium. Belgian Hip Fracture Study Group. Osteoporosis International 2000, 11:373-380.
23. Reginster J.Y., Gillet P., Ben Sedrine W., Brands G., Ethgen O., de Froidmont C., et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 1999, 15:507-514.
24. Gabriel S.E., Tosteson A.N., Leibson C.L., Crowson C.S., Pond G.R., Hammond C.S., et al. Direct medical costs attributable to osteoporotic fractures. Osteoporosis International 2002, 13:323-330.
25. Melton L.J., Gabriel S.E., Crowson C.S., Tosteson A.N., Johnell O., Kanis J.A. Cost-equivalence of different osteoporotic fractures. Osteoporosis International 2003, 14:383-388.
26. Zethraeus N., Borgstrom F., Strom O., Kanis J.A., Jonsson B. Cost-effectiveness of the treatment and prevention of osteoporosis-a review of the literature and a reference model. Osteoporosis International 2007, 18:9-23.
27. Hiligsmann M., Ethgen O., Richy F., Reginster J.Y. Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcified Tissue International 2008, 82:288-292.
28. Kanis J.A., Johnell O., Oden A., Jonsson B., De Laet C., Dawson A. Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 2000, 27:585-590.
29. Hiligsmann M., Bruyere O., Reginster J.Y. Cost-utility of long-term strontium ranelate treatment for postmenopausal osteoporotic women. Osteoporosis International 2010, 21:157-165.
30. Stock J.L., Bell N.H., Chesnut C.H., Ensrud K.E., Genant H.K., Harris S.T., et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. American Journal of Medicine 1997, 103:291-297.
31. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. Journal of Clinical Endocrinology and Metabolism 2000, 85:3109-3115.
32. Schousboe J.T., Ensrud K.E., Nyman J.A., Melton L.J., Kane R.L. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women. Journal of the American Geriatrics Society 2005, 53:1697-1704.
33. Tosteson A.N., Jonsson B., Grima D.T., O'Brien B.J., Black D.M., Adachi J.D. Challenges for model-based economic evaluations of postmenopausal osteoporosis interventions. Osteoporosis International 2001, 12:849-857.
34. Strom O., Borgstrom F., Sen S.S., Boonen S., Haentjens P., Johnell O., et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries-an economic evaluation based on the fracture intervention trial. Osteoporosis International 2007, 18:1047-1061.
35. Belgian Center for Pharmacotherapeutic Information. Available from URL: [Accessed 1 May 2009]. http://www.cbip.be/GGR/MPG/MPG_NI.cfm%23MP_04090.
36. Kanis J., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International 2008, 19:399-428.
37. Gold D.T. Medication adherence: a challenge for patients with postmenopausal osteoporosis and other chronic illnesses. Journal of Managed Care Pharmacy 2006, 12:S20-S25. quiz S26-8.
38. Osterberg L., Blaschke T. Adherence to medication. New England Journal of Medicine 2005, 353:487-497.
39. Balkrishnan R., Jayawant S.S. Medication adherence research in populations: measurement issues and other challenges. Clinical Therapeutics 2007, 29:1180-1183.
40. Vermeire E., Hearnshaw H., Van Royen P., Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. Journal of Clinical Pharmacy and Therapeutics 2001, 26:331-342.
41. Strom O., Borgstrom F., Kanis J.A., Jonsson B. Incorporating adherence into health economic modelling of osteoporosis. Osteoporosis International 2010, 20:23-34.
42. Huybrechts K.F., Ishak K.J., Caro J.J. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 2006, 38:922-928.
43. Briggs A., Sculpher M., Claxton K. Modelling methods for health economic evaluation 2006, Oxford University Press, New York.
44. Gleeson T., Iversen M.D., Avorn J., Brookhart A.M., Katz J.N., Losina E., et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporosis International 2009, 20:2127-2134.
45. Rietbrock S., Olson M., van Staa T.P. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 2009, 102:35-42.
46. Earnshaw S.R., Graham C.N., Ettinger B., Amonkar M.M., Lynch N.O., Middelhoven H. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates. Current Medical Research and Opinion 2007, 23:2517-2529.
47. Cotte F.E., Cortet B., Lafuma A., Avouac B., Hasnaoui A.E., Fardellone P., et al. A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 2008, 75:201-208.
48. Danese M.D., Badamgarav E., Bauer D.C. Effect of adherence on lifetime fractures in osteoporotic women treated with daily and weekly bisphosphonates. Journal of Bone and Mineral Research 2009, 24:1819-1826.
49. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcified Tissue International; 2010 [Epub Ahead of Print].
50. Hiligsmann M, Gathon HJ, Bruyere O, Ethgen O, Rabenda V, Reginster JY. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health; 2010 [Epub Ahead of Print].
51. Sambrook P. Compliance with treatment in osteoporosis patients-an ongoing problem. Australian Family Physician 2006, 35:135-137.
52. Penning-van Beest F.J., Goettsch W.G., Erkens J.A., Herings R.M. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clinical Therapeutics 2006, 28:236-242.
53. Rossini M., Bianchi G., Di Munno O., Giannini S., Minisola S., Sinigaglia L., et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporosis International 2006, 17:914-921.
54. Delmas P.D., Vrijens B., Eastell R., Roux C., Pols H.A., Ringe J.D., et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 2007, 92:1296-1304.
55. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. Journal of Clinical Endocrinology and Metabolism 2004, 89:1117-1123.
56. Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clinical Therapeutics 2001, 23:1296-1310.
57. Brookhart M.A., Avorn J., Katz J.N., Finkelstein J.S., Arnold M., Polinski J.M., et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. American Journal of Medicine 2007, 120:251-256.
58. Cherry S.B., Benner J.S., Hussein M.A., Tang S.S., Nichol M.B. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009, 12:489-497.
59. Cleemput I., Kesteloot K., Vanrenterghem Y., De Geest S. The economic implications of non-adherence after renal transplantation. Pharmacoeconomics 2004, 22:1217-1234.
60. Salas M., Hughes D., Zuluaga A., Vardeva K., Lebmeier M. Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature. Value Health 2009, 12:915-922.